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Abstract
Background: HIV-1 exhibits a high degree of genetic diversity and is presently divided into 3 distinct HIV-1 genetic groups
designated major (M), non-M/non-O (N) and outlier (O). Group M, which currently comprises 9 subtypes (A-D, F-H, J and K),
at least 34 circulating recombinant forms (CRFs) and several unique recombinant forms (URFs) is responsible for most of the
HIV-1 epidemic. Most of the current knowledge of HIV-1 central nervous system (CNS) infection is based on subtype B.
However, subtypes other than subtype B account for the majority of global HIV-1 infections. Therefore, we investigated
whether subtypes have any influence on cerebrospinal fluid (CSF) markers of HIV-1 CNS infection.
Methodology/Principal Findings: CSF HIV-1 RNA, CSF neopterin and CSF white blood cell (WBC) count were measured in
patients infected with different HIV-1 subtypes. Using multivariate regression analysis, no differences in the CSF WBC count,
neopterin and viral load were found between various HIV-1 subtypes.
Conclusions: We did not find any subtype-dependent differences in the markers evaluated in this study.
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Introduction
The genetic diversity of HIV-1 and the biological properties of
the different subtypes might be important factors in the
pathogenesis, transmissibility and clinical progression of the
infection[1]. Some studies have reported that HIV-1 subtype has
no significant impact on disease progression [2–5], while others
have provided evidence that differences might exist [6–8]. For
instance subtype D has been suggested to have greater virulence
than subtype A [9,10]
HIV-1 infection is characterized by a spectrum of neurological
complications throughout its course, occurring either as a direct
consequence of the HIV-1 infection itself or due to opportunistic
infections and/or tumours [11–13]. AIDS Dementia Complex
(ADC), the most severe manifestation of HIV-1 central nervous
system (CNS) infection, developed in approximately 20 % of
patients with advanced HIV-1 infection before the widespread use
of antiretroviral treatment[14]. ADC is considered the result of a
complex interplay between the effects of viral replication and
immune activation in the brain, which ultimately lead to neuronal
injury and death [15–18].
Cerebrospinal fluid (CSF) HIV-1 RNA and neopterin are two of
the most extensively studied surrogate markers of HIV-1 CNS
infection. HIV-1 RNA can be detected in the CSF of virtually all
untreated patients irrespective of disease stage [19]. Neopterin is a
marker of cell-mediated immune activation produced by cells of
the macrophage lineage upon stimulation by interferon-c [20].
Increased CSF neopterin concentrations are found in HIV-1-
infected patients with AIDS, ADC [21] or with opportunistic CNS
infections, but moderately elevated levels are also frequently found
in asymptomatic HIV-1-infected individuals [22].
There is very sparse information available on the role of
different subtypes in HIV-1 infection of the CNS. Even though the
majority of HIV-1 infections in the world are caused by other
subtypes, our knowledge of HIV-1 related neurological disease is
based mainly on subtype B. Moreover, the extent of HIV-1
induced neurocognitive impairment in regions where HIV-1 is
highly prevalent remains largely unknown, although some recent
studies have begun to address this issue[23–26]. These studies
have shown varying results[27]. For instance, an Ugandan study
showed an ADC prevalence of 31% in HIV-1 infected patients
[25], while a blinded study of HIV-1 positive and negative
Ethiopian subjects found no significant differences between the
two groups[23]. Since Ugandan patients are predominantly
infected with subtype D and Ethiopians with subtype C, this
finding dictates further investigation into the role of subtype in
HIV-1 CNS infection [27]. Subtype differences in co-receptor
usage, disease progression rate as well viral diversity could
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disease[24] .
The aim of this study was to determine whether subtype has any
influence on CSF markers of infectious activity.
Materials and Methods
Participants
Archived data from 128 neurologically asymptomatic HIV-1
infected patients who underwent lumbar punctures in a prospec-
tive research cohort at the Department of Infectious Diseases,
Sahlgrenska University Hospital, Go ¨teborg, Sweden were includ-
ed. The CSF was handled, analysed and stored immediately after
collection according to protocol. Patients were specifically queried
regarding neurological problems and clinically examined. The
patients were either treatment naı ¨ve (n=124) or had been off
treatment for at least 6 months (n=4). Demographics and clinical
characteristics of the study participants are presented in Table 1.
Laboratory methods
HIV-1 RNA was quantified in cell-free CSF and plasma using
the Roche Amplicor Monitor assay (version 1.0 and 1.5, Hoffman
La-Roche, Basel, Switzerland). Neopterin was measured in CSF
and serum using a commercially available radio-immunoassay
(Henningtest Neopterin, BRAHMS, Berlin, Germany). The
normal reference value for neopterin was #5.8 nmol/L in CSF
and #8.8 nmol/l in serum [28]. Routine assessments also
included CSF white blood cell (WBC) counts and peripheral
blood CD4 cell count determinations.
Subtypes were identified by the Stanford HIV Reverse
Transcriptase (RT) and Protease (PR) Sequence Database
(http://hivdb.stanford.edu) [29] using consensus RT and PR
sequences obtained through an in-house method. Plasma HIV-1
RNA was extracted using the Magnapure Total Nucleic Acid
isolation kit (Roche) according to the manufacturer’s protocol. The
outer primers RT1 (59-CTGTACCAGTAAAATTAAA-GCCA-39),
RT2 (59-TATGTCATTGACAGTCCAGCT -39),PR1(59- CCGA-
TAGACAAGGAACT -39)a n dP R 2( 5 9- TCTACTAATGCTTT-
TATTTTT -39) were used in the first round polymerase chain
reaction (PCR). The reaction mixture contained 8 units RNasinH
(Promega),4unitsAMV(Promega),200 mMofeachdNTP(Roche),
1 unit AmpliTAQ DNA polymerase (ABI), anti-TAQ as recom-
mended by the manufacturer (Clontech), 200 nM of the each of the
outer primers, 60 mM KCl, and 2.0 mM MgCl2 in 20 mM Tris-
HCl buffer. The amplification program in the first PCR cycle was
60 min at 43uC then 2 min 30s at 94uC followed by 40 cycles with
settings 20 s at 94uC, 20 s at 50uC, and 60 s at 72uC. The final cycle
was 5 min at 72uC and a final incubation at 8uC.
The next step was a second (nested) PCR with a mixture
consisting of 5 ml of the first PCR product and the same reagents
as in the first PCR excluding RNasinH and AMV, and the inner
primers RT3 (59- ATGGCCATTGACAGAAGAAA39), RT4 (59-
AGGCTGTACTGTCCATTTAT-39), PR 3 (59- ACTTCCCT-
CAGATCACTCTT-39) and PR 4 (59- TTCCTGGCTTTAA
TTTTACT- 39). The amplification steps in the nested PCR were
the same as in the first PCR except for the omission of the first step
of 60s at 43uC. All PCR reactions were carried out in GenAmpH
PCR system 9600 (ABI).
The nested PCR product was separated by agarose gel
electrophoresis of 15 ml of the master mix on 1.8 % agarose,
containing 0.25 mg ethidium bromide per ml, and visualized by
UV illumination.
Table 1. Demographic and clinical characteristics of the study patients.
Genetic subtype
B C CRF01_AE CRF02_AG A D
Number of patients 54 (42%) 34 (27%) 16 (12%) 9 (7%) 9 (7%) 6 (5%)
Sex
Male 48 17 11 6 8 3
Female 6 17 5 3 1 3
Origin
European 46 8 7 1 2 0
African 1 26 3 7 7 5
Asian 3 0 6 1 0 0
South American 4 0 0 0 0 1
Transmission route
Blood products 1 2 1 0 0 0
Heterosexual 22 31 13 8 8 6
Homosexual 23 0 0 0 0 0
I V D U 811 01 0
Unknown 0 0 1 1 0 0
Age (median, range) years 37 (23–68) 33 (18–59) 37 (17–58) 30 (23–51) 34 (26–67) 36 (23–49)
CDC stage
A 3 22 81 2 7 55
B 532 02 0
C1 7 3 2 2 2 1
CDC–Centers for Disease Control and Prevention; IVDU–Intravenous drug use
doi:10.1371/journal.pone.0001971.t001
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Purification Kit (Qiagen) prior to cycle sequencing with Big Dye
Terminator Ready Reaction Kit version 1.1 (ABI Prism).
Nucleotidesequences were analyzed onthe ABIPrism 3100 Genetic
Analyzer sequencer and aligned with Sequence Navigator software.
Statistical analysis
Plasma and CSF HIV-1 RNA were log10 transformed before
statistical analysis. Because of the skewed distributions of several of the
study variables, median and interquartile range (IQR; 25th -75th
percentile) were used for descriptive statistics. Mann-Whitney’s (two
independent samples) and Kruskall Wallis (several independent
samples) tests were used for comparisons. Spearman’s rank correlation
coefficient was used for evaluation of correlations. Linear multiple
regression was performed on the CSF markers to evaluate the effect of
different subtypes. CSF neopterin was log transformed for the
multivariate analysis. Four outliers were removed from the CSF WBC
count before the multivariate analysis. The removal of outliers was the
best way to transform the CSF WBC count data and was done by a
statistician. A P-value of ,0.05 was considered significant.
Results
Subtype was successfully assigned in both the RT and protease
sequences in all but six samples that could be identified only by
protease (2B, 2A, and 1CRF01_AE) or by RT (1CRF01_AE)
sequence analysis. Figure 1 shows the results of the descriptive
statistics for HIV-1 RNA and neopterin in CSF and plasma/
serum, the CSF WBC count, the CSF/blood HIV-1 RNA and
neopterin quotients and the CD4 cell count. All but four patients
had elevated CSF neopterin concentrations. The median CSF
neopterin levels (Panel A) were highest in patients with subtypes B
and C but this difference did not reach statistical significance.
Seven out of the 128 patients (5%) had CSF HIV-1 RNA below
the detection limit of 50 copies/ml. Panel B and D show the CSF
HIV-1 RNA and the CSF/plasma HIV-1 RNA quotients with
median values that were in the same range in all the subtypes. The
median CSF/serum neopterin quotients in panel C were higher in
subtypes C and D although this difference was not significant.
Most of the patients with subtype C and half of those with subtype
D had significantly higher neopterin levels in CSF than in serum,
which would explain the higher CSF/serum neopterin quotients.
This was independent of disease stage.
A significant subtype dependent difference was found in the
CSF WBC count (p,0.05) in the Kruskall Wallis test (Panel E). A
statistically significant difference in the CSF WBC count was
found between subtype B and subtype C (p,0.05) when
comparing individual subtypes. However, subtype did not prove
to be a significant independent predictor for any of the CSF
markers in the multiple regression analysis when all the other CSF
Figure 1. Boxplots of the cerebrospinal fluid (CSF) and plasma/serum levels of HIV-1 RNA and neopterin, the CSF/P-RNA and CSF/S-
neopterin quotients, the CD4+ T- lymphocyte and the CSF white blood cell (WBC) counts according to subtype. The number of
available samples is shown by n. The P-values on the top right of each panel are calculated using Kruskall-Wallis test. The bar inside the box shows
the median values, the bottom and top hinges of the box represent the 25th and 75th percentile. The dotted lines represent the normal reference
values. Outliers are depicted by o, extremes by *. Circulating recombinant forms CRF01_AE and CRF02_AG are designated as AE and AG.
doi:10.1371/journal.pone.0001971.g001
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patient origin, age and sex along with subtype were included as
independent variables (data not shown). The CD4 cell count, CSF
and plasma HIV-1 RNA were significant independent predictors
of CSF WBC count. Patients with subtype D had the lowest CD4
cell counts (Panel F) while those carrying the subtype CRF01_AE
had the highest serum neopterin concentrations (Panel G). The
median Plasma HIV-1 RNA levels (Panel H) were in the same
range throughout the subtypes. A subtype-independent analysis
showed a significant correlation between CSF HIV-1 RNA and
CSF neopterin (rs=0.45, p,0.0001).
Discussion
We did not find any significant subtype-specific differences in
the neuromarkers investigated in this study. CSF HIV-1 RNA and
neopterin are two of the most studied markers of HIV-1 CNS
infection. These markers reflect processes implicated in the
pathogenesis of HIV-1 infection of the CNS, which makes them
appropriate to study. Although the number of subjects studied was
relatively low, especially for subtypes other than B and C, there are
no larger CSF studies published on HIV-1 subtypes and CSF
markers of infectious activity. The number of patients without
antiretroviral treatment included would be sufficient to detect any
larger differences between subtypes. Minor differences are of
course not possible to detect.
We found a statistically significant difference in the CSF WBC
count between subtypes B and C in the univariate analysis where
subjects with subtype C had more CSF cells than those with
subtype B. This result could not be verified in the multivariate
analysis when all other independent variables were taken into
account. Subtype B included more patients with advanced disease
compared to subtype C, which probably explains this difference.
A slightly increased CSF WBC count that wanes in advanced
systemic infection is a frequent finding in HIV-1 infected patients
with or without symptoms [30,31]. In a subtype-independent
analysis, patients with CD4 ,50 had significantly less CSF
pleocytosis (data not shown) than those with more preserved CD4
cell counts, which is in agreement with previous studies. The CSF
pleocytosis was correlated to the CSF viral load and inversely
correlated to the plasma viral load, which also is in agreement with
previous findings [30,31].
A limitation in the study is that no patients with ADC were
included, mirroring the fact, that ADC is nowadays uncommon in
areas with access to antiretroviral treatment. Another limitation is
that disease duration was unknown in a majority of cases. A
longitudinal prospective study design would have been preferable
to identify differences. These days, studies of this kind are not
possible to conduct due to treatment intervention.
There were more patients who had suffered an AIDS defining
illness in the subtype B group compared to the other groups which
in its turn is explained by the change in the epidemiology of HIV-1
infection in Sweden and most of Europe: in the Pre-HAART era
the majority of patients were of European origin, carrying subtype
B. In the HAART-era, new infections are mostly diagnosed in
individuals who acquired their infection in other parts of the world
where other subtypes are predominant. Differences in origin and
gender between subjects with different subtypes were taken into
account in the multivariate analysis.
If subtype has little impact on susceptibility to CNS HIV-1
infection, which factors are then important? Host factors,
coexisting morbidities and co-infections in combination with viral
virulence factors might be more important than subtype. As yet,
the role of these factors has been very little studied. Why some
patients suffer from high CSF viral loads and/or signs of
intrathecal immune activation while others exhibit only minor
signs of CNS infectious activity remains unknown.
Conclusions
We did not find any differences in CSF biomarkers of CNS
infectious activity between subtypes in neurologically asymptom-
atic, untreated HIV-1 infected individuals.
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